News FDA turns down Hetlioz for jet lag once again Vanda will continue to push for approval of Hetlioz for jet lag, despite the FDA saying its trial designs were not satisfactory.
Market Access ISPOR Glasgow with EVERSANA: Perspectives on JCA, PICO, and ... At ISPOR EU 2025, a cross-stakeholder panel addressed how Joint Clinical Assessment under the EU HTA Regulation is reshaping evidence strategies.
Digital Sponsored Clinical trials at the core: Decentralised, AI targeted, ESG... For Inventus' Steve Sanghera and Jim Michel 2025 was a year of progress in clinical trial enablement.
News Sanofi seeks use of type 1 diabetes drug in younger kids Sanofi could be months away from wider US approval for Tzield, its drug for delaying the progression of type 1 diabetes, in children as young as one.
News FDA declines to approve Corcept's rare disorder drug As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to Corcept by turning down its new Cushing's drug.
Digital Healthcare Predictions for the UK in 2026 Digital systems are steadily replacing legacy software and automation tools roll out at speed to cut back the time clinicians spend on manual tasks.
News FDA knocks back Pharming's bid for wider Joenja use The FDA has turned down Pharming's bid to broaden the label of Joenja for rare immunodeficiency disorder APDS so it can be used in younger patients.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
